This webinar is aimed at informing end-users involved in pre-clinical drug screening (discovery and development) of the models and techniques available to elucidate the causes and consequences of gastrointestinal (GI) toxicities and pathologies. This information will ultimately help users design dose schedules and formulations that can minimise such effects, or quickly identify test articles that have a high likelihood of toxicity in vivo or in the clinic. Dr. Booth has been a key opinion leader is this field for 25 years, working with many different biotechnology and pharmaceutical companies to design and perform studies that address their pertinent questions. This webinar will review some of the models in use and discuss current practice when running pre-clinical studies for sponsors at Epistem. Specifically, there will be an overview of:
- The implications of the timings of observed toxicity
- The consequences of interrupted cell production or cell death in various tissue populations
- The techniques available to measure perturbed barrier function
- Predictive in vitro screening techniques to identify articles likely to cause in vivo toxicity
Historical data will be presented to illustrate the techniques and responses to known therapeutics, along with typical study designs and readouts.
The aim of this webinar is to enable the end-user to select the best model and study design to predict or assess GI toxicity.
Cath Booth, PhD, Co-founder and Managing Director, Contract Research Services, Epistem
Dr. Booth received her PhD in 1991 from the University of Cambridge, England, after completing her studies at the multi-Nobel prize winning MRC Laboratory of Molecular Biology. Subsequently, she spent 10 years within academic research, working in Professor Chris Potten’s laboratory at The Paterson Institute for Cancer Research, Manchester, England. This work focussed on epithelial biology, particularly the control of cell turnover in the gastrointestinal epithelium, and the role of the stem cells and apoptosis in controlling epithelial damage and repair following radio- or chemotherapy. She co-founded Epistem with Professor Potten in 2000, in order to harness this in-depth knowledge to assist biotechnology and Pharmaceutical companies with their pre-clinical discovery and development portfolios. Dr. Booth has published over 60 papers, spoken at many international conferences and performed a key advisory role for pertinent U.S. Government bodies, the U.S. FDA, and for numerous companies on this subject matter. Most recently, Dr. Booth has been involved in developing validated models of gastrointestinal radiation damage in order to evaluate novel therapies
Who Should Attend?
Chief Scientific Officers (CSO), Senior Executives, Directors, Team Leaders and Senior Scientists involved in understanding, predicting or controlling off-target or on-target/off-tissue toxicity to the intestinal epithelium.
Relevant job areas or roles:
- Pre-clinical Development
- Pre-clinical Pharmacology
- Pre-clinical Research
- Pre-clinical Drug Development
- Discovery Scientists
- Pharmaceutical Toxicologists
Epistem is a UK biotechnology company operating three distinct business divisions.
The Contract Research Division, presenting this webinar, has been operating for 16 years and delivers innovative pre-clinical research services with an in-depth specialist understanding of epithelial tissues. Pre-clinical model areas include oncology (inc. leukaemia), oncology treatment associated side effects (such as mucositis), inflammatory diseases such as IBD, RA and psoriasis, and wound healing and skincare. Each area is supported by core technologies including histology, immunohistochemistry, FACS, multiplexing, laser capture microdissection and gene expression profiling, which also provide independent services to external sponsors that perform their own in-house models. All solutions are delivered via an individual sponsor specific tailored approach.